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During the purification of rat atria1 natriuretic factor (ANF), low, intermediate and high h4, forms were 
observed. In this report we describe the purification and amino acid sequence of a 73 residue peptide 
containing at its C-terminus the previously sequenced 33 amino acid ANF peptide. The cleavage necessary 
to produce the 33 amino acid ANF from the 73 amino acid precursor occurs at a Leu-Leu bond. We also 
report the amino acid composition of an even longer form of ANF containing about 103 residues, in which 
the extension is amino terminal to the 73 peptide. A computer data bank search showed that the 
determined sequence is a novel one and is not homologous to any known proteins or segment hereof. The 
natriuretic activity of the 73 amino acid form when compared to that of a synthetic ANF peptide, 
comprising the sequence of the last 26 amino acids of ANF, was found to be slightly lower. 
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1. INTRODUCTION 
During the last year, a large effort was devoted 
to the purification and chemical characterization 
of the rat natriuretic factor from homogenates of 
heart atria. We recently reported the isolation and 
amino acid sequence of 4 homologous low M, pep- 
tides containing the active natriuretic sequence and 
showed that the native and synthetic replicas ex- 
hibited comparable biological activity. These short 
forms of ANF contained 33, 32, 31, and 26 amino 
acids representing amino terminal truncated ver- 
sions of the 33 amino acid form [1,2]. Two other 
groups of investigators have as yet only reported 
the amino acid composition of similar ANF pep- 
tides and no sequence data are yet available for 
comparison [3,4]. 
As previously reported [ 1,2], elongated forms of 
ANF were observed during the purification of the 
rat atria1 natriuretic factor. These are now further 
subdivided into intermediate and high iki, forms of 
ANF based on amino acid composition and 
molecular sieving chromatography. We present he 
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complete purification and sequence analysis of one 
of the intermediate forms and show that it is com- 
posed of 73 amino acids in which the amino ter- 
minal 40 amino acids precede the sequence of the 
previously reported 33 peptide. Furthermore, 
preliminary amino acid analysis and sequence sug- 
gest that one of the high A4, forms of ANF could 
contain up to 103 amino acids in which the 33 ANF 
peptide is again at the C-terminus. 
2. MATERIALS AND METHODS 
2.1. Biological assay 
The natriuretic activity of the native and syn- 
thetic peptides was measured by a biological assay 
as in [5,6]. Briefly the native or synthetic ANFs 
were injected as a bolus of 1 ml in Krebs solution 
(pH 7.4) via a catheter inserted in the jugular vein 
of 200 g female Sprague-Dawley rats. Urine was 
collected for a 20 min period in preweighed vials. 
A constant infusion of 5% dextrose (2.1 ml/h) was 
given throughout the experiment. Results are ex- 
pressed as peq. Na excreted for a collection period 
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of 20 min from which the sodium excretion of the 
control period has been subtracted. 
2.2. ~r~~cat~~~ of the high M, ~~r~ of ANI: 
The homogenization of 48 g of atria (650 rats), 
extraction of ANF by Cl9 Sep-Pak cartridges and 
gel filtration on &o-Gel P-10 were done as in [l] 
except that the homogenisation buffer contained 
5 mM instead of 1 mM EDTA. From the Bio-Gel 
P-10 column, 3 successive regions of different Mr 
containing active material were pooled. These 
regions were designated low (~~), in- 
termediate (6000-10000) and high (10~15~) 
Iw, forms. Each region was then further purified 
separately using a CM-Bio-Gel A cohmm, a Mono 
S HR5/5 column and a CN a-Bondapak column 
followed by a Cl8 a-Bondapak column as in [l]. 
Final purification was achieved on a Cls p- 
Bondapak column eluted with 0.13010 (v/v) hep- 
ta~uorobut~ic acid and acetonitrile. 
2.3. Amino acid and sequence analysis 
Amino acid analyses of the native or reduced 
and carboxymethylated peptides were done in 
duplicate following hydrolysis in 5.7 N HCI in 
vacua at 108°C for 24 h. The separation and quan- 
titation of the amino acids were done as in f2]. 
The amino terminal Edman degradation on the 
reduced z&d carboxymethylated elongated form of 
ANF was performed using a 0.3 M Quadrol pro- 
gram and 3 mg Polybrene (~drich) [7] on a 
Beckman 890C sequenator equipped with a Se- 
quemat P-6 autoconverter and a model SC-510 
controller. Phenylthiohydantoins (PTHs) were 
identified and quantitated by HPLC (81, using a 
Varian 5500 liquid chromat~~aph equipped with a 
Vista 402 plotter/integrator. 
3. RESULTS AND DISCUSSION 
A large degree of peptide heterogeneity was 
observed during the various purification steps of 
the atrial natriuretic factor. At least 15 related pep- 
tides could be purified from 48 g of atria obtained 
from 650 rats. Initial molecular sieving on Bio-Gel 
P-10 allowed the crude subdivision of the various 
active molecular entities into low, intermediate and 
high Mr forms of ANF. The low 1M, forms have 
been previously shown by sequence to be com- 
posed of at least 4 amino terminal truncated ver- 
sions of a parent 33 amino acid ANF peptide [1,2]. 
All these homologous forms were shown to be 
highly active and of similar potency to a synthetic 
replica of ANF 8-33 [Z], 
From the intermediate and high MI pools we 
were able to detect’7 elongated forms of ANF. 
Since the recovered mounts of most of these pep- 
tides were too low to allow further sequence 
characterization only 2 peptides obtained in yields 
between 50 and 1OOpg were analysed extensively. 
These longer forms of ANF purified by reverse- 
phase HPLC on a C~S p-Bondapak column using 
the trifluoroacetic acid/acetonitrile system [l] 
eluted around 35% acetonitrile, whereas the 
previously reported shorter forms [1,2] eluted bet- 
ween 22 and 26% acetonitrile. Final purification of 
the longer forms of ANF was achieved on a Cl8 p- 
Bondapak column eluted with the hep- 
tafluorobutyric acid/acetonitrile system. The two 
peptides so purified are denoted ANF-Hl and 
ANF-H2. Fig.1 illustrates the elution profile of 
ANF-HI in this final purification step. In this elu- 
tion system, basic peptides are known to elute at a 
higher acetonitrile concentration as compared to 
the trifluoroacetic acid system. Indeed, ANF-Hl 
and ANF-H2 elute around 40% acetonitrile. 
Table 1 gives the amino acid composition of 
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Fig.1. Chromatography of the peptide ANF-HI on Cl8 
r-Bondapak column eluted with 30-50% acetonitrile in 
0.13% heptafluorobutyric a id at a slope of O.Z%/min 
and a flow rate of 1 ml/min. 
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Table 1 
Amino acid composition of ANF peptides 
Amino 
acid 
ANF-HI ANF-Hl ANF-H2 ANF 
SEQ’ l-33 
Asx 
Thr 
Ser 
Glx 
Pro 
CLY 
Ala 
Val 
Met 
Be 
Leu 
Tyr 
Phe 
His 
LYS 
Arg 
Cysb 
Trp 
Total 
6.42(6) 6 
1.05(l) 1 
8.42(9) 9 
4.42(4) 4 
6.69(6-7) 6 
10.69( 11) 11 
5.49(5) 5 
2.05(2) 2 
0 (0) 0 
1.91(2) 2 
8.19(S) 8 
0.91(l) 1 
2.13(2) 2 
0.17(O) 0 
1.53(1-2) 2 
9.45(9-10) 10 
n.d. 2 
n.d. 2 
67-70’ 73 
8.32(8) 2 
1.09(l) 0 
8.95(9) 5 
11.12(11) 1 
9.02(9) 1 
10.38(10) 6 
8.89(9) 2 
3.98(4) 0 
1.55(2) 0 
2.00(2) 2 
11.99(12) 3 
1.08(l) 1 
2.34(2) 2 
0.32(O) 0 
3.19(3) 0 
10.44(10) 6 
2.2 (2) 2 
n.d. 0 
95c 33 
a ANF-Hl SEQ, the calculated ANF-HI amino acid 
composition based on the determined sequence. This 
also applies to the values of ANF l-33 obtained in [2] 
b For ANF-HZ the Cys content was quantitated as 
carboxymethylcysteine. Otherwise for ANF-HI the 
Cys was not determined (n.d.) since the composition 
was made on the native peptide 
’ This represents the calculated presumed total number 
of amino acids excluding Trp and Cys for ANF-Hl 
and excluding Trp for ANF-HZ. These values have to 
be confirmed by sequence 
Numbers in parentheses represent he nearest integer 
both ANF-Hl and ANF-H2, together with that of 
ANF l-33 deduced from its previously reported se- 
quence [2]. First, it can be seen that ANF-Hl and 
ANF-H2 are composed of approx. 70 and 95 
amino acids, respectively. Furthermore, the 
presence of the same proportions of Ile, Tyr and 
Phe as compared to ANF l-33 suggests that these 
peptides could represent elongated forms of ANF. 
However, the composition does not allow precise 
localization of the extension nor does it provide ir- 
revocable proof that these peptides are indeed 
elongated forms of ANF. For this purpose only 
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amino acid sequencing can answer these questions 
unambiguously. 
Fig.2 shows the identification and yield of the 
various PTH-amino acids obtained during the se- 
quence of ANF-Hl . The repetitive and initial yield 
for this sequence were computed from the linear 
regression line to be 94.2% and 4.97 nmol respec- 
tively with a correlation coefficient of 0.959. 
Clearly, this sequence proves that ANF-Hl 
represents an N-terminal extended form of ANF. 
This is evidenced by an 18 amino acid overlapping 
sequence starting at residue 41 of ANF-Hl which 
is identical to the first 18 amino acids of ANF 1-33 
[2], as illustrated in fig.3. Based on the amino acid 
compositions of ANF-Hl and ANF l-33 (table l), 
together with the known presence of a single C- 
terminal Tyr in ANF l-33, and the sequence shown 
in fig.2, it can be concluded that ANF-Hl is com- 
posed of 73 amino acids of which the last 32 amino 
acids (residues 41-73) represent the previously 
described sequence of ANF l-33 (fig.3). Therefore, 
the obtainment of ANF l-33 from ANF-Hl in- 
volves a cleavage between Leu40-Leu41. Such a 
Leu cleavage was also previously observed to occur 
within ANF l-33, yielding the N-terminal trun- 
cated versions ANF 2-33 and ANF 8-33 [22]. 
Preliminary sequence data on ANF-H2 revealed 
that this peptide represents an N-terminally 30 
amino acid extended form of ANF-HI, giving a 
total of 103 amino acids, thus providing evidence 
as to the relatedness of ANF-H2 to ANF l-33. This 
result agrees reasonably well with the amino acid 
composition of ANF-HZ (table 1). 
In order to verify the relatedness of the sequence 
of the 73 amino acid ANF-Hl to that of any 
known peptides or proteins and segments thereof, 
a computer data bank search was performed using 
the National Biomedical Foundation Mutation 
data Matrix program and Sequence Data Bank, 
Georgetown University, Washington, DC. When 
compared to the 2700 protein sequences in the data 
bank, no significant homology (>30%) was 
found. This confirms the novel nature of the se- 
quence determined, similar to what was originally 
observed for the sequence of ANF l-33 [2]. 
The natriuretic activity of the 73 amino acid 
ANF-Hl is compared to the synthetic ANF 8-33 [2] 
(amino acids 48-73 in fig.3) in fig.4. As expected 
ANF 8-33 gives a dose-response curve which levels 
off around 1000 pmol to produce a natriuretic 
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Fig.2. Automatic NHz-terminal degradation of the ANF-Hl peptide. Quantitative yields of PTH-amino acids 
normalized to a PTH-norleucine internal standard are illustrated as a function of residue numbers. The slope and 
intercept were obtained by a linear regression analysis on selected stable PTH-amino acids giving the repetitive yield 
and initial yield respectively. 
response of 350 peq. Na/20 min. For comparison, 
only two doses of ANF-Hl could be used due to 
scarcity of the material. The observed natriuretic 
activity of ANF-Hl appears to be slightly lower 
than that of ANF 8-33 for the doses used (fig.4). 
It is rather surprising that this 73 amino acid form 
of ANF should cause a similar natriuretic effect to 
that of ANF l-33. A possible explanation for this 
observed behavior could be the proteolysis of 
ANF-Hl in circulation once injected into the 
animal thereby releasing the active moiety. Alter- 
natively, the 40 residue N-terminal extension may 
not change the conformation of the active se- 
quence enough to cause the loss of biological ac- 
tivity. These hypotheses would, however, have to 
be verified experimentally. 
In conclusion, it can now be stated that the 
atrium contains a potent natriuretic factor which is 
synthesized in the form of a precursor molecule 
containing at least 103 amino acids, of which the 
C-terminal 26 amino acids are enough to exhibit 
the potency of the observed natriuresis. Further 
work will be necessary to complete the amino acid 
sequence of the original mRNA translation form 
of ANF, which will be easier to achieve by 
molecular cloning. For this purpose the sequence 
of ANF-Hl provided should be useful to devise 
nucleotide probes for hybridization experiments 
355 
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NH2 - Glu - “.I - Pro - Pro - Trp - Tbr - Cl, - oh, - “.I - A= - 
10 00 
Pro - ser - G1n - Ar# - Asp - my - wy - Ala - La” - my - 
20 so 
Al8 - ny - Pro - Trp - ‘asp - Pro - SW - **p - Art - .s*r - 
35 40 
4la - Lau - Leu - Lys - ser - r.y* - Le” - Ar# - Al. - La” 4 
40 00 
Leu - Al. - my - Pro - *r# - se* - Le” - Art - .4r# - ser - 
05 00 
ser - cya - Pbe - CIy - my - A=* - Ile - Asp - Art - I,e - 
I 00 70 
my - Ala - Oh - .ser - Cly - Le” - ny - cys - Am - ser - 
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Fig.3. Complete amino acid sequence of ANF-Hl 
peptide. The arrow points to the junction between the 
first 40 amino acids and the beginning of the sequence 
of ANF l-33 [2], emphasizing the Leu40-Leu41 cleavage 
necessary in order to produce ANF l-33. The disulfide 
bridge between cysteines occupying positions 52 and 68 
is also indicated. 
I 
10 
Fig.4. Dose-response curve of synthetic ANF (8-33) and 
of ANF-Hl (high M, ANF) on natriuresis. Each dose is 
the mean ( f SE) of at least 3 individual determinations. 
ACKNOWLEDGEMENTS 
We are grateful to Dr R.F. Nutt of Merck, 
Sharp and Dohme Laboratories, West Point, PA, 
who supplied us with synthetic ANF (8-33). We 
thank Mrs S. Diebold and Mrs S. Olivieri for their 
excellent echnical work and Mrs D. Marcil for her 
secretarial help. This work was supported by the 
Medical Research Council of Canada (R.G. and 
G.T.) and the Hypertension Group of the Clinical 
Research Institute of Montreal, and by a Program 
Grant (PG-2) from the MRC (M.C., N.G.S., 
C.L.). C.L. is ‘chercheur-boursier’ from the 
FRSQ. 
REFERENCES 
VI 
121 
]31 
141 
i51 
PI 
[71 
PI 
Thibault, G., Garcia, R., Seidah, N.G., Lazure, C., 
Cantin, M., Chretien, M. and Genest, J. (1983) 
FEBS Lett. 164, 286-290. 
Seidah, N.G., Lazure, C., Chretien, M., Thibault, 
G., Garcia, R., Cantin, M., Genest, J., Nutt, R.F., 
Brady, S.F., Lyle, T.A., Paleveda, W. J., Colton, 
C.D., Ciccarone, T.M. and Weber, D.F. (1984) 
Proc. Natl. Acad. Sci. USA, in press. 
De Bold, A.J. and Flynn, T.G. (1983) Life Sci. 33, 
297-302. 
Grammer, R.T., Fukunu, H., Inagami, T. and 
Misono, KS. (1983) Biochem. Biophys. Res. Com- 
mun. 116, 696-703. 
Garcia, R., Cantin, M., Thibault, G., Ong, H. and 
Genest, J. (1982) Experientia 38, 1071-1073. 
Thibault, G., Garcia, R., Cantin, M. and Genest, J. 
(1983) Hypertension 5 (suppl.l), 1-75-I-80. 
Seidah, N.G., Rochemont, J., Hamelin, J., Lis, M. 
and Chretien, M. (1981) J. Biol. Chem. 256, 
7977-7984. 
Lazure, C., Seidah, N.G., Chretien, M., Lallier, R. 
and St-Pierre, S. (1983) Can. J. Biochem. Cell. Biol. 
61, 287-292. 
aimed at the obtainment of a cDNA probe for 
ANF. This is especially evident from the presence 
of two strategically located tryptophan residues 
within the first 25 amino acid sequence of ANF- 
Hl. 
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